 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
UNC Researchers Report New Details on Role of miR-122 in HCV
December 20, 2012
UNC Researchers Report New Details on Role of miR-122 in HCV
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UNC Teams Uncovers How HCV Uses miR-122 to Survive
January 5, 2012 / Gene Silencing News - Santaris Nears End of Phase II Trial of miRNA HCV Rx, Seeks Partnership Since GSK Opted Out
September 15, 2011 / Gene Silencing News - EPO to Hear Mirrx Request for Resumption of Patent Proceedings Covering miRNA Rx Technology
January 20, 2011 / Gene Silencing News - Santaris Pharma to Begin Phase II Development of miRNA-Targeting HCV Drug
September 23, 2010 / Gene Silencing News - Santaris Sues Mirrx Founder Over Blockmir Technology
May 6, 2010 / Gene Silencing News